We’re driving systemic change to improve care, support and equity for the millions of people living with schizophrenia and psychosis spectrum disorders. Our programs align with the pillars of our 10-Year Strategic Plan, and focus on solving foundational problems that create barriers to treatment, support and survival.
The Schizophrenia & Psychosis Action Alliance solves foundational problems that create barriers to treatment, support and survival for people living with schizophrenia and those who care for them. Our programs align with the pillars of our 10-Year Strategic Plan: Research, Education & Care and Advocacy & Public Policy.
We are solving foundational problems that create barriers to treatment, support and survival for people living with schizophrenia and those who care for them.
Accelerate earlier diagnosis and breakthrough treatments and uncover the societal, caregiver and patient costs of schizophrenia to improve resources for care.
S&PAA co-hosted the first Externally Led Patient-Focused Drug Development Meeting on schizophrenia to make what matters to those living with the disease a higher priority in drug development and the FDA review process. Our resulting Voice of the Patient report was published in 2023.
S&PAA is part of the National Institutes of Health’s AMP-SCZ Steering Committee to help improve schizophrenia treatments and treatment outcomes by identifying early indicators of the severe brain disease.
S&PAA sits on the Steering Committee of this Stanley Center for Psychiatric Research program to gain insight into disease mechanisms (molecular and cellular “triggers”), stratify patients within the disease spectrum and validate candidates for drug development by seeking and analyzing biomarkers in cerebrospinal fluid.
S&PAA provides patient perspectives and expertise to industry organizations to accelerate the development of innovative treatment approaches for people with schizophrenia and psychosis spectrum disorders.
S&PAA’s survey of caregivers of adults with schizophrenia or schizoaffective disorder spotlighted the severe brain disease’s negative impact on finances, career and family lives.
S&PAA’s Societal Costs of Schizophrenia Impact & Related Disorders report revealed that the severe brain disease costs the US $281.6 billion per year.
Provide resources for individuals, families and healthcare professionals to improve patient and caregiver outcomes.
S&PAA launched our first continuing professional education program in 2023 to advance provider knowledge of state-of-the-art methods for treating schizophrenia and infuse the perspective of those living with the disease. Hundreds of clinicians have completed the program to date.
Drive systemic change to fix our broken healthcare system and create equitable access to high-quality care for people with schizophrenia.
On World Schizophrenia Day, S&PAA organized our first Day of Action, driving 3 events to address system-wide barriers to care for people living with schizophrenia.
Our impact grows with every donation. Together, we can create a healthcare system where every individual, regardless of their condition, is treated with respect and dignity.
